On 13 November 2026 the FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy at risk of progression. For US nephrology brand and market access teams, the label is only the first gate.
The US Food and Drug Administration (FDA) on 13 November 2026 approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy who are at risk of disease progression, to induce remission of proteinuria, which means protein in the urine. The FDA calls this the first drug approved specifically for the treatment of these adults.
Primary membranous nephropathy is a rare kidney disease. The immune system attacks the glomeruli, the tiny filters in the kidneys that clean waste from the blood. The filters become inflamed and damaged, and large amounts of protein leak into the urine. Patients can develop high cholesterol, high blood pressure, severe swelling, fatigue, kidney failure and other complications.
The evidence behind the decision is MAJESTY, a Phase 3 study of 142 adults followed for 104 weeks. Complete remission at week 104 was 36% on Gazyva and 6% on tacrolimus, a medicine the FDA says is sometimes used off-label here. That is a clear result. It is also not a coverage decision, and it is not a map of which nephrology practices will move from off-label habits to the label.
What the FDA actually approved
The approved use is narrow and should be quoted carefully. Gazyva is approved "to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria." It is an approval of a new use for a medicine already on the market, not a new molecule.
Gazyva is given as an intravenous infusion, meaning it is delivered into a vein in a clinic or infusion suite, not taken as a tablet. The current US prescribing information, updated for this indication in November 2026, sets the recommended dose for primary membranous nephropathy at 1,000 mg at the first infusion, then at weeks 2, 24 and 26. Retreatment is two 1,000 mg doses given two weeks apart, no sooner than 16 weeks after the last dose.
The application received Breakthrough Therapy, Orphan Drug and Priority Review designations. Breakthrough Therapy is an FDA programme for drugs that may show substantial improvement over available therapy for a serious condition. Orphan Drug status is for rare diseases. Priority Review shortens the FDA's review clock. None of these designations is a coverage decision.
The FDA notice does not name the sponsor. Gazyva is marketed in the United States by Genentech, a member of the Roche Group, which filed the supplemental Biologics License Application (sBLA), a request to add a new use to an already licensed medicine. In a 14 July 2026 release, Genentech said the FDA had already granted Breakthrough Therapy designation in April 2026 and was expected to decide by November 2026. I found no Genentech or Roche approval press release dated 13 November 2026, so the FDA notice and the updated label are the primary public records of the decision itself.
What MAJESTY showed, and what it did not
MAJESTY (NCT04629248) was a Phase 3, randomized, controlled, open-label, multicenter study in 142 adults with primary membranous nephropathy. "Randomized" means patients were assigned by chance. "Open-label" means patients and investigators knew which treatment was given. "Multicenter" means more than one trial site took part. The main study period was 104 weeks, just over two years. Patients were assigned to Gazyva or to tacrolimus.
The primary endpoint, the main result the study was built to measure, was the share of patients who reached complete remission of proteinuria at week 104. The FDA defines that as a urine protein-creatinine ratio (UPCR) of no more than 0.3 g/g, with a stable estimated glomerular filtration rate (eGFR), a blood-test measure of how well the kidneys filter, and without rescue therapy, treatment failure or leaving the study early. UPCR is a standard way to measure how much protein is leaking into the urine.
On that endpoint, the FDA reported a clear gap: 36% of patients on Gazyva reached complete remission at week 104, compared with 6% on tacrolimus.
Genentech had already published more precise figures when it announced priority review on 14 July 2026: 36.9% versus 5.7%, an adjusted difference of 31.1 percentage points, with a 95% confidence interval of 18.2 to 44.0 and p<0.001. Those numbers were also presented at the 63rd European Renal Association Congress in June 2026 and published in the New England Journal of Medicine. I use the FDA's 36% versus 6% as the official approval figures, and treat Genentech's 36.9% versus 5.7% as the company's reported trial result. They describe the same study.
Genentech also said Gazyva was superior to tacrolimus on overall remission (complete or partial remission) at week 104, and on complete remission at week 76. The FDA announcement does not report those secondary endpoints. It also does not report an effect on long-term kidney function. The official benefit is complete remission of proteinuria at two years, as the FDA defined it.
Two caveats belong next to the headline number. First, the study was open-label, so knowledge of the assigned drug could have influenced how some outcomes were assessed, even with a lab-based primary endpoint. Second, 142 adults is a substantial trial for a rare disease, but it is still a modest base from which to forecast national use.
Safety sits on the label for a reason
Gazyva's label carries a boxed warning, the FDA's strongest warning, for two risks. The first is hepatitis B virus reactivation, meaning a prior hepatitis B infection can become active again. The second is progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection caused by a virus in people with a weakened immune system.
In the primary membranous nephropathy study, the FDA says the most common side effects were infusion-related reactions and upper respiratory tract infection. The label directs readers to the full prescribing information for complete safety details. Those warnings will matter to prescribers, to infusion sites and, in time, to payers writing prior-authorisation criteria.
This is the second kidney label in seven weeks
Gazyva was not new to kidney care on 13 November. The FDA says it was already approved for certain cancers, for active lupus nephritis, and for childhood-onset idiopathic nephrotic syndrome. Lupus nephritis is kidney inflammation caused by lupus. That makes primary membranous nephropathy Gazyva's third US kidney-related indication, and its second in seven weeks.
The earlier of those two recent labels came on 25 September 2026. The FDA approved Gazyva to reduce the risk of relapse in adults and children aged 2 years and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. Idiopathic means the cause is not known. Nephrotic syndrome is a pattern of heavy protein loss in the urine, low blood protein and often swelling. That decision is listed on the FDA's Notable Approvals page, dated 25 September 2026, the same date Genentech confirmed in its own statement.
Seven weeks is a short gap between two rare-kidney labels. For brand teams, that is an opportunity and a complication. The same medicine now has two new kidney uses on a short clock, plus an earlier lupus nephritis label. Infusion sites, billing staff and nephrology practices will have to keep the populations, doses and evidence packages straight. We have written before about Gazyva's lupus nephritis access outside the United States. The US question now is how three kidney labels sit together in the same specialty.
A label is not a coverage decision
This is the point I would put first in any launch discussion. An FDA approval means the agency has concluded that the drug is safe and effective for the use on the label. It does not mean Medicare, Medicaid or a commercial plan will pay for it, or on what terms.
US payers make that decision on their own clock. They may ask for step therapy, meaning a patient tries another treatment first. They may ask for prior authorisation, a formal request before the infusion is given. They may limit use to patients who match the trial more tightly than the label, or to certain sites of care. Our guide to FDA evidence versus payer evidence sets out why registration data and coverage data are not the same file.
Gazyva is an infusion, so the payment path is likely to run through the medical benefit rather than the pharmacy counter, especially for Medicare Part B. Site of care will matter: hospital outpatient departments, community infusion centres and nephrology clinic chairs do not have the same economics. Our analysis of the Medicare GLOBE model and Part B account-level change is a reminder that infused products in the US are won or lost account by account, not only in a national policy memo.
As of 15 November 2026 I have not seen a public national coverage decision, a published US list price for this new use, or a payer policy written specifically for primary membranous nephropathy. Until those appear, the approval is a licence to sell, not proof of access.
Uptake will move practice by practice
Tacrolimus is already in use, off-label, in this disease. That is not a footnote. It is the starting point for demand.
Some nephrology practices will move quickly once a labelled option exists, especially where they have been waiting for one. Others will stay with the habits they know until they see coverage rules, infusion capacity and longer follow-up. A national uptake curve that averages those two groups will look flat for a while, then misleading.
The first field question is therefore not "what share of the US market converts in year one?" It is: which nephrology practices move from off-label tacrolimus to on-label Gazyva, in which health systems, and what do their payers ask for before the first infusion is booked?
Genentech has estimated the US incidence of primary membranous nephropathy at 1.2 per 100,000 people per year, and has said that, left untreated, up to 30% of patients progress to kidney failure over 10 years (14 July 2026). An incidence figure is not a treated, eligible or paid-for population. It is a starting point for sizing, not a forecast.
What is still not known
Before anyone builds an uptake model, it is worth listing what the public record does not yet say:
- Coverage. No public national coverage determination, and no commercial or Medicare Advantage policy I could find that is specific to this new use.
- Price. No US list price or net price has been published for this indication in the sources I reviewed.
- Coding and site of care. The updated label describes the dose and the infusion, but it does not settle where the drug will be given or how it will be billed in practice.
- EMA and other regulators. In July, Genentech said MAJESTY data were also being filed with other health authorities, including the European Medicines Agency (EMA). I found no public EMA decision as of 15 November 2026, so European timing should not be assumed.
- Long-term kidney outcomes. The FDA announcement reports complete remission of proteinuria. It does not report a proven effect on slowing the loss of kidney function.
- How the three kidney labels will be managed in the same clinic. The public record does not yet show how practices will separate lupus nephritis, childhood-onset idiopathic nephrotic syndrome and adult membranous nephropathy in scheduling, stocking and reimbursement.
The research questions that matter now
In my view, the regulatory story is mostly told. The commercial story is not. For US nephrology brand, medical and market access teams, whether at Genentech or at a company watching the same specialty, these are the questions I would want answered with evidence rather than assumptions.
1. Which practices switch first, and why? Structured interviews with nephrologists in large group practices, academic centres and community clinics can show who is ready to move from off-label tacrolimus, who will wait for payer policy, and what evidence would change their mind. A later quantitative survey can size those groups.
2. What will payers actually require? Pharmacy and medical directors at national plans, regional plans and Medicare Advantage organisations will set the rules. Interviews can map likely prior-authorisation criteria, any expected step through other immunosuppressants, and whether they will treat the FDA's 36% versus 6% result as sufficient, or ask for more on kidney function, durability or cost.
3. How does site of care change the economics? An infusion given in a hospital outpatient department, a community infusion centre or a nephrology clinic chair is not the same product commercially. Account research should map where eligible patients are already infused, what capacity those sites have, and which sites will be slow to add a new kidney protocol.
4. How do clinicians weigh benefit against the boxed warning? Complete remission at two years is the efficacy story. Hepatitis B reactivation and PML are the safety story. Research should test how much the boxed warning narrows the eligible pool in real clinics, including screening steps before the first dose.
5. How will three kidney labels sit in one specialty? Practices that already use Gazyva for lupus nephritis, or that have started to use it for childhood-onset idiopathic nephrotic syndrome, may adopt the new adult label faster. Or they may blur the populations. Mapping current Gazyva experience inside nephrology accounts is a practical first cut.
6. What do patients and caregivers actually face after approval? Referral to infusion, travel time, time off work and out-of-pocket cost will shape persistence. Patient research can show where the path breaks, especially if coverage is delayed or restricted.
7. What real-world evidence should start now? Payers will eventually ask what happens outside the 142-person trial: who is treated, who reaches remission, who discontinues, and what happens to kidney function. That work is easier if the cohort definitions are set before the first claims appear. Our US real-world evidence and market access guide covers how to design that file so it can be used with payers later.
Who gains, who waits, and what a sceptic would say
Possible winners. Adults with primary membranous nephropathy who, for the first time, have a medicine approved specifically for their disease. Genentech and Roche, which add a third US kidney-related use to a product already used in cancer and lupus nephritis. Nephrology practices that have been using tacrolimus off-label and now have a labelled alternative with a clear two-year remission result.
Possible losers, or at least the parties under new pressure. Off-label tacrolimus use in this disease, if practices and payers move. Infusion sites that have to absorb a new protocol without new staff. Payers, if demand appears before policy is written.
The sceptic's case. A sceptic would say that "first approved drug" is a regulatory milestone, not a patient-access outcome. They would note that MAJESTY was open-label, that the FDA's benefit is proteinuria remission rather than a proven delay of kidney failure, that the boxed warning is serious, and that without published coverage rules the commercial story is still theoretical. All of those points are fair, and they are exactly the gaps research can close.
What to watch next
- Payer policies. The first Medicare Advantage, Medicaid and large commercial medical policies for this use, including any step therapy or site-of-care rules.
- Price and coding. A published US price, billing codes and any guidance on the medical benefit pathway.
- Prescribing information updates. Any further FDA label changes once more safety or dosing questions arise in use.
- European and other filings. An EMA opinion, or decisions in other countries, following the filings Genentech said were under way in July.
- Early account signals. Which large nephrology groups and health systems add Gazyva for this use to their protocols, and how fast infusion volume follows.
What US nephrology brand and market access teams should do now
- Separate the label from the access plan. Keep an FDA evidence file and a payer evidence file. Do not treat the 36% versus 6% result as a coverage argument on its own.
- Map nephrology accounts before building a national forecast. Identify which practices already use off-label tacrolimus, which already infuse Gazyva for another kidney label, and which payers sit in front of those accounts.
- Test prior-authorisation language with payers now, while policies are still being written, not after they are locked.
- Run physician research on the boxed warning and on site of care, because both will cap real-world use even where the label is welcomed.
- Set a real-world evidence plan in the first months, with clear cohort rules, so later payer reviews are not built from whatever claims happen to appear.
How BioNixus helps
BioNixus has run healthcare market research since 2012, with 118 clients in 48 countries and 127 studies in 2026 so far. Our physician network includes more than 82,000 physicians globally and about 3,200 in the Middle East. US work is delivered from our USA office, which is the Americas office and global HQ, in Sheridan, Wyoming.
For nephrology brand and market access teams, we run physician insights studies with nephrologists and infusion-site leads, market access research with US payers on coverage criteria and site of care, and real-world evidence design that can be used after launch. See our United States healthcare market research page for local capabilities, and our FDA real-world evidence guide for how US regulatory evidence and payer evidence differ.
If you need physician or payer evidence on which nephrology practices will move from off-label tacrolimus to the Gazyva label, and what their payers will ask for, contact BioNixus and we can scope the study within 48 hours. Visit bionixus.com to learn more.
